Chemical Probes for the Functionalization of Polyketide Intermediates**

Elena Riva, Ina Wilkening, Silvia Gazzola, W. M. Ariel Li, Luke Smith, Peter F. Leadlay, and Manuela Tosin*

Abstract: A library of functionalized chemical probes capable of reacting with ketosynthase-bound biosynthetic intermediates was prepared and utilized to explore in vivo polyketide diversification. Fermentation of ACP mutants of S. lasaliensis in the presence of the probes generated a range of unnatural polyketide derivatives, including novel putative lasalocid A derivatives characterized by variable aryl ketone moieties and linear polyketide chains (bearing alkyne/azide handles and fluorine) flanking the polyether scaffold. By providing direct information on microorganism tolerance and enzyme processing of unnatural malonyl-ACP analogues, as well as on the amenability of unnatural polyketides to further structural modifications, the chemical probes constitute invaluable tools for the development of novel mutasynthesis and synthetic biology.

As direct outcomes of millions of years of structural and functional evolution, natural products remain at the forefront of drug discovery and development. Polyketides in particular constitute a highly diverse family including important pharmaceuticals and agrochemicals such as the antibiotic erythromycin A, the cholesterol-lowering agent lovastatin, the antiparasitic ivermectin, and the immunosuppressant rapamycin. Polyketides are biosynthesized in microorganisms and plants by the polyketide synthase (PKS) multi-enzymes. PKSs utilize a wide range of bioavailable acyl building blocks (e.g. acetate, propionate, butyrate, etc.) and iterative decarboxylative Claisen condensation to generate stereoenriched enzyme-bound polyketide chains, which are eventually released from PKSs and can be further enzymatically tailored to yield the final bioactive products. Natural product structural diversification is highly desirable to obtain novel molecules of increased efficiency and/or novel bioactivity. Synthetic biology is currently seen as a highly promising avenue to generate novel polyketide derivatives, especially in the context of modular PKSs. This potential arises because of the relative amenability of these assembly lines to genetic manipulation by domain swap and other redesign. Current approaches towards the generation of unnatural polyketides (compounds which are still made by enzymatic assembly but are structurally different from the original products) include semisynthesis, precursor-directed biosynthesis, mutasynthesis, combinatorial biosynthesis, and chemogenetics. Chemical synthesis as well as enzyme and metabolic engineering can be utilized to provide polyketide machineries with unnatural building blocks. Recent efforts in these directions have highlighted both the innate and engineered chemical flexibility of PKSs in accepting a variety of non-native substrates to generate novel polyketide derivatives in vitro and in vivo, thus opening up the exploitation of novel chemical spaces and bioactivities for this class of natural products. We have recently developed synthetic chain terminators capable of capturing polyketide biosynthetic intermediates in vitro and in vivo. These chemical probes (e.g., the β-ketoacids 1.a.b; Scheme 1: generated in situ from the hydrolysis of the corresponding methyl esters) compete with ACP-bound malonate units for polyketide chain extension. By reacting with enzyme-bound biosynthetic intermediates, intermediate-like species 2.a.b are off-loaded from PKSs and become available for LC-MS characterization. Further, the use of these molecules in vivo has allowed us to reveal relatively inaccessible features of polyketide assembly, such as the timing of ring formation in the biosynthesis of the polyether antibiotic lasalocid A.

In characterizing the captured biosynthetic intermediate species, it occurred to us that it might be possible, by utilizing further derivatized chemical probes together with suitably engineered bacterial strains, to rapidly generate a variety of novel polyketide intermediates and products bearing bioorthogonal chemical handles for site-specific modifications.
such as alkyne and azide moieties,[12] as well as pharmaceutically relevant motifs, such as fluorine.[13] To test our hypothesis, we prepared a small library of second-generation methyl ester probes characterized by the variation of the N-acyl moiety and 1,3-dicarbonyl functionalization (3–13; Scheme 2). We then employed these molecules as substrates in small-scale fermentations (10 mL) of ACP mutant strains of *Streptomyces lasaliensis*. The strains, constructed from *S. lasaliensis* NRRL 3382 by point mutation of the active serine (for 4'-phosphopantetheine attachment) of ACP12 and ACP5 to alanine residues as previously reported,[11b] do not produce the natural polyketide product lasalocid A. However they still harbour enzyme-bound biosynthetic intermediates.[11b] The esters 3–13 were hydrolyzed in situ to the corresponding β-ketoacids 1 and 14–23 by endogenous esterases, with the extent of the hydrolysis being substrate-dependent (see the Supporting Information).

The overall outcome of the feeding experiments is summarized in Scheme 2 and Table 1 (see the Supporting Information for details). In the ethyl acetate extracts of the ACP12 (S970A) mutant, grown in the presence of the methyl ester substrates 3–8 (supplemented daily to reach a 2.5–4.0 mM final concentration), the putative lasalocid A derivatives 2 and 24–28 were identified as the major polyketide products off-loaded from the *lasA* PKS by micro-LC-HR-MS analyses (Table 1, entries 1–7). The compounds 2 and 24–28 were characterized by HR-MS and displayed a conserved fragmentation pattern involving McLafferty rearrangement and subsequent formation of *m/z* 377, a diagnostic polyether fragment.[11b] In addition, for the compounds 27 and 28 the loss of the C10 acyl chain occurring during fragmentation afforded an *m/z* 260 fragment, which would correspond to a protonated cyclic imine (Figure 1c and see the Supporting Information) and strongly supports the aromatic ketone nature of these derivatives. The formation of 24–28 indicates that variations of the N-acyl moiety of the pseudomalonate substrates are well tolerated by both *S. lasaliensis* and the *lasA* PKS in the range of concentrations utilized in these experiments. Interestingly, additional formation of short-chain products (e.g., the pentaketides 38–40) was observed for long-chain substrates (7–8, and, later on, 13; Table 1, entries 6, 7, and 19). The nature of these products was independently verified by feeding of *S. lasaliensis* ACP5 (S3799A) with 7 and 8 (entries 9 and 10). Putative iso-lasalocid derivatives (29–30) were also selectively obtained.
Table 1: Generation of putative unnatural polyketides from the lasA PKS and the substrates 1 and 14–23 (generated from in vivo hydrolysis of 3–13; Scheme 2).

| Entry | S. lasaliensis strain | Substrate[^a] | Ester acid | R[^b] | R[^c] | Major product(s)[^d] |
|-------|----------------------|---------------|------------|-------|-------|----------------------|
| 1     | ACP12 (S970A)        | 3a            | 1a         | CH,
| 2     | ACP12 (S970A)        | 3b            | 1b         | CD,
| 3     | ACP12 (S970A)        | 4             | 14         | CF,
| 4     | ACP12 (S970A)        | 5             | 15         | (CH2)2C≡CH, H
| 5     | ACP12 (S970A)        | 6             | 16         | (CH2)2C≡CH, H
| 6     | ACP12 (S970A)        | 7             | 17         | (CH2)2CH,
| 7     | ACP12 (S970A)        | 8             | 18         | (CH2)2CH2,
| 8     | ACP5 (S3799A)        | 3             | 13         | (CH2)2C≡CH, H
| 9     | ACP5 (S3799A)        | 7             | 17         | (CH2)2CH2,
| 10    | ACP5 (S3799A)        | 8             | 18         | (CH2)2CH2,
| 11    | ΔlasB-ACP12 (S970A)  | 6             | 16         | (CH2)2CH,
| 12    | ΔlasB-ACP12 (S970A)  | 8             | 18         | (CH2)2CH2,
| 13    | ACP12 (S970A)        | 9             | 19         | (CH2)2C≡CH, CH3
| 14    | WT (NRRL 3382)       | 9             | 19         | (CH2)2C≡CH, CH3
| 15    | WT (NRRL 3382)       | 10            | 20         | CH2
| 16    | ACP12 (S970A)        | 11a           | 21a        | CH2
| 17    | ACP12 (S970A)        | 11b           | 21b        | CD2
| 18    | ACP12 (S970A)        | 12            | 22         | (CH2)2C≡CH, F
| 19    | ACP12 (S970A)        | 13            | 23         | (CH2)2CH2,

[^a]: Methyl ester hydrolyzed in vivo to the corresponding acid (see boxed inset in Scheme 2). [^b]: Major product(s) as deduced by LC-HRMS analysis. [^c]: Double peaks (for both sodium and ammonium adducts) detected, possibly arising from isomers/conformers. [^d]: Detected in minor amounts.

Figure 1. UPLC-HR-MS analyses of the ethyl acetate extracts of S. lasaliensis ACP12 (S970A) grown in the presence of substrate 8 (Table 1, entry 7). a) TIC and extracted ion chromatogram traces showing the presence of the compound 28 (Acquity HSS T3 column, 78-minute gradient). b) HR-MS and c) HR-MS² of the putative lasalocid derivative 28. The double LC-MS peak for 28 and all the other putative lasalocid derivatives is under investigation.

when the compounds 6 and 8 were fed to S. lasaliensis ΔlasB-ACP12 (S970A) (entries 11 and 12). These derivatives displayed a similar HR-MS² fragmentation pattern to their lasalocid putative counterparts but eluted at significantly different retention times, as previously observed (see the Supporting Information).

1,3-dicarbonyl functionalization of the chemical probes led to further unexpected results. From the fermentation of S. lasaliensis ACP12 (S970A) in the presence of the N-pentenyol 2-methyl hexanoate substrate 9, the novel putative polyether derivative 31 was obtained and characterized by HR-MS² (Table 1, entry 13). This product indicates that the last ketosynthase (KS) domain of the lasA PKS is capable of carrying out chain extension with a methyl malonate mimic in place of the natural malonate, followed by ketoreduction and dehydrogenation. As a result, the normal chain aromatization does not take place and a chemically derivatized linear polyether is generated instead. Oxidized undecaketides such as 35 and 36 were initially identified as the major species generated from the lasA PKS in wild-type S. lasaliensis grown in the presence of the methylmalonate mimics 9 and 10 (entries 14 and 15). Conversely, the use of an engineered strain in conjunction with a newly optimized feeding protocol for liquid cultures has herein favored the unprecedented formation of linear oxidized dodecaketides such as 31. Intriguingly, when the N-acetyl- and deuterocetyl-2-fluoro hexanoates 11a and 11b, respectively, were employed as substrates for S. lasaliensis ACP12 (S970A), the corresponding fluorinated undecaketides 37a and 37b were identified as the main products off-loaded from the PKS (entries 16 and 17), with the oxidized linear dodecaketides 33a,b barely detectable. No obvious products were identified from the feeding of S. lasaliensis...
ACP12 (S970A) with the N-pentynyl 2-fluoro substrate 12 (entry 18), whereas from the N-decanoyl 2-fluoro substrate 13, the fluorinated putative polyether 34 was afforded, albeit in minor amount compared to the short-chain products 40–43 (entry 19; all products characterized by HR-MS, see the Supporting Information).

These results show for the first time that, by directly utilizing fluoromalonate surrogate substrates in vivo, fluorine can be successfully incorporated into advanced polyketide biosynthetic intermediates and products at specific α-carbonyl positions in place of hydrogen atoms, and methyl and ethyl groups with unexpected consequences on the natural product assembly. Indeed for the lasA PKS the stage and the extent of fluorine incorporation is dependent on the N-acyl length of the probe (Table 1). Additionally, the absence of oxidized undecaketide species bearing fluorine seems to suggest that 2-fluorinated undecaketide dienes may not be suitable substrates for epoxidation/epoxide hydrolysis leading to polyether formation. These findings are of particular relevance in view of engineering the production of fluorinated polyketides for medicinal chemistry and chemical biology applications.

Most of the polyketide products arising from these experiments also bear an alkyne or an azide moiety. To show how these molecules can be creatively diversified, the putative lasalocid A derivatives 25, 26, and 28 were utilized as substrates for azide–alkyne Huisgen cycloaddition and Staudinger-phosphite reactions in crude and purified organic extracts of S. lasaliensis cultures (Figure 2). In particular, the crude putative lasalocid alkyne derivative 25 was reacted with the N-Boc-cadaverine azide 44 in the presence of copper(I) to afford the putative lasalocid conjugate 45. The same transformation was carried out on HPLC-purified fractions of 25, thus leading to identical click products (Figure 2a). The putative azide polyethers 26 and 28 were converted into glucose conjugates (e.g., 47) by click reactions with the alkyne 46, and to phosphoramidates (e.g., 48) by reaction with trimethyl phosphate (Figures 2b–c).

Overall the compounds 2, 24–28, 31–36 and their derivatives were identified and characterized as putative lasalocid A species by HR-MS, all displaying the conserved 

![Figure 2](image-url)

**Figure 2.** a) Conversion of the putative lasalocid alkyne derivative 25 into the cadaverine conjugate 45 by copper-catalyzed azide–alkyne cycloaddition (CuAAC) with the azide 44 (carried out in crude and purified organic extracts, as shown in upper and lower selected LC-MS ion traces, respectively (Acquity HSS T3 column, 68-minute gradient). b) The putative lasalocid azide derivative 26 is converted into the glucose conjugate 47 by CuAAC with the alkyne 46 (Acquity HSS T3 column, 68-minute gradient). c) The putative lasalocid azide derivative 28 is converted into the phosphoramidate 48 by a Staudinger-phosphite reaction (Eclipse C18 column, 35-minute gradient). The presence of a double LC-MS peak for all the newly generated putative lasalocid derivatives is under investigation.
polyketides in the bacterial crude extracts (Figure 1). From comparative LC-MS analyses with samples of lasalocid A of known titre, we have preliminarily estimated the production of the unnatural polyethers to be in the range of 100–800 μg L⁻¹, depending on the probe utilized and in the conditions here reported (data not shown). Nonetheless, we have shown here that such diverse and functionalized products can be straightforwardly generated from the fermentation of a minimally engineered Streptomyces strain in the presence of varied synthetic malonate surrogates (3–13), they can be isolated by HPLC purification and they can be further derivatized (Figure 2).

To the best of our knowledge, 2, 24–28, 31–36, 45, 47, and 48 together constitute the first example of an unnatural polyether library characterized by the replacement of the aryl carboxylate functionality with variable aryl ketones (2, 24–28, 45, 47, and 48) and with linear polyketide chains flanking the polyether portion of the natural product (31–36). Polyether ionophores are widely utilized as antibiotics in veterinary medicine, and they are also rapidly emerging as promising bioactive molecules for cancer therapy[^17] and for the treatment of tropical diseases.[^18] Structural modification of polyethers can change the ability and the selectivity of metal cations and small-molecule binding.[^19] Therefore this approach may give access to novel molecules of therapeutic interest, as well as helping illuminate their mechanism of action.

On the basis of the results reported here, it is also appealing to envisage the generation of a library of polyketide derivatives by a novel mutasynthetic approach involving chain re-initiation of stalled biosynthetic intermediates on any ketosynthase with a variety of malonyl-ACP mimics. N-acetyl cysteamine analogues of malonate extender units and of advanced biosynthetic intermediates are widely used in current mutasynthetic approaches in place of the natural substrates bound to the pantetheinyl cofactor of acyl carrier proteins.[^20,9,20b] It is now clear that the pantetheinyl portion of acyl carrier proteins can be replaced by a variety of N-acyl groups of variable chain length and nature to generate functionalized polyketides. This feature is of particular interest in relation to the newly available three-dimensional structure of a whole PKS module,[^20] as molecular modeling should be now employed to design unnatural malonyl-ACP analogues capable of best interacting with all the catalytic partners in the PKS reaction chamber. In light of all of these considerations, we are currently exploring whether the mutasynthetic approach to the putative lasalocid precursor/derivative structures reported herein is an effective and general approach applicable to other PKSs and modular assembly lines for the generation of novel unnatural products.

In summary, the functionalized chemical probes 3–13 constitute first-hand chemical biology tools for exploring novel polyketide diversification by providing direct information on PKSs tolerance and processing of unnatural malonyl-ACP analogues, as well as on the amenability of the newly generated unnatural polyketides to further synthetic modifications. Our current work is focusing on the large-scale isolation of the novel polyketide derivatives reported here, their full characterization by NMR spectroscopy, and the evaluation of their bioactivity, as well as on the development of tools to enhance their production in vivo. The application of the probes 3–13 for the investigation and exploitation of other PKS systems will be reported in due course.

Received: July 21, 2014
Published online: September 11, 2014

Keywords: biosynthesis · enzymes · drug discovery · polyketides · synthetic methods

[^1]: D. Newman, G. M. Cragg, *J. Nat. Prod.* 2012, 75, 311–335.
[^2]: K. J. Weissman, *Methods Enzymol.* 2009, 459, 3–16.
[^3]: G. T. Carter, *Nat. Prod. Rep.* 2011, 28, 1783–1789.
[^4]: M. Cummings, R. Breitling, E. Takano, *FEBS Microbiol. Lett.* 2014, 351, 116–125.
[^5]: J. Cortes, K. E. Wiesmann, G. A. Roberts, M. J. Brown, J. Staunton, P. F. Leadlay, *Science* 1995, 268, 1487–1489.
[^6]: M. Olijnyk, M. J. B. Brown, J. Cortes, J. Staunton, P. F. Leadlay, *Chem. Biol.* 1996, 3, 833–839.
[^7]: a) C. J. Rowe, I. U. Bohm, I. P. Thomas, B. Wilkinson, B. A. M. Rudd, G. Foster, A. P. Blackaby, P. J. Sidebottom, Y. Roddis, A. D. Buss, J. Staunton, P. F. Leadlay, *Chem. Biol.* 2001, 8, 475–485; b) A. Bhatt, C. B. W. Stark, B. M. Harvey, A. R. Gillimore, Y. Demydchuk, J. B. Spencer, J. Staunton, P. F. Leadlay, *Angew. Chem. Int. Ed.* 2005, 44, 7075–7078; *Angew. Chem.* 2005, 117, 7237–7240; c) S. Kushnir, U. Sundermann, S. Yahiaoui, A. Brockmeyer, P. Janning, F. Schulz, *Angew. Chem. Int. Ed.* 2012, 51, 10664–10669; *Angew. Chem.* 2012, 124, 10820–10825; d) L. Laureti, L. Song, S. Huang, C. Corre, P. Lelibond, G. L. Challs, B. Aigle, *Proc. Natl. Acad. Sci. USA* 2011, 108, 6258–6263.
[^8]: a) R. J. M. Goss, S. Shankar, A. Abou Fayad, *Nat. Prod. Rep.* 2012, 29, 870–889; b) A. Kirschning, F. Hahn, *Angew. Chem. Int. Ed.* 2012, 51, 4012–4022; *Angew. Chem.* 2012, 124, 4086–4096.
[^9]: a) T. Knobloch, K. Harmroofs, F. Tať, B. Thomaszewski, F. Sasse, A. Kirschning, *ChemBioChem* 2011, 12, 540–547; b) J. M. Winter, G. Chioù, I. R. Bothwell, W. Xu, N. K. Garg, M. Luo, Y. Tang, *Org. Lett.* 2013, 15, 3774–3777; c) I. Koryakina, J. B. McArthur, M. M. Draelos, G. J. Williams, *Org. Biomol. Chem.* 2013, 11, 4449–4458; d) M. C. Walker, B. W. Thuronyi, L. K. Charkoudian, B. Lowry, C. Khosla, M. C. Y. Chang, *Science* 2013, 341, 1089–1094; e) U. Sundermann, K. Bravo-Rodriguez, S. Klopries, S. Kushnir, H. Gomez, E. Sanchez-Garcia, F. Schulz, *ACS Chem. Biol.* 2013, 8, 443–450.
[^10]: a) M. Tosin, D. Spitteler, J. B. Spencer, *ChemBioChem* 2009, 10, 1714–1723; b) M. Tosin, L. Betancor, E. Stephens, W. M. A. Li, J. B. Spencer, P. F. Leadlay, *ChemBioChem* 2010, 11, 539–546.
[^11]: a) M. Tosin, Y. Demydchuk, J. S. Parascandolo, C. Blasco-Per, F. J. Leeper, P. F. Leadlay, *Chem. Commun.* 2011, 47, 3460–3462; b) M. Tosin, L. Smith, P. F. Leadlay, *Angew. Chem. Int. Ed.* 2011, 50, 11930–11933; *Angew. Chem.* 2011, 123, 12136–12139.
[^12]: a) E. M. Sletten, C. R. Bertozzi, *Angew. Chem. Int. Ed.* 2009, 48, 6974–6998; *Angew. Chem.* 2009, 121, 7108–7133; b) M. Grammel, H. C. Hang, *Nat. Chem.* 2013, 5, 475–484.
[^13]: a) S. Purser, F. R. Moore, S. Swallow, V. Gouverneur, *Chem. Soc. Rev.* 2008, 37, 320–330; b) J. Wang, M. Sánchez-Roselló, J. L. Aceña, C. del Pozo, A. E. Sorochnisky, S. Fuster, V. A. Solo-phonok, H. Liu, *Chem. Rev.* 2014, 114, 2432–2506; c) I. Ojima, *J. Org. Chem.* 2013, 78, 6358–6383; d) M. C. Walker, M. C. Y. Chang, *Chem. Soc. Rev.* 2014, 43, 6527–6536.
[^14]: V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, *Angew. Chem. Int. Ed.* 2002, 41, 2596–2599; *Angew. Chem.* 2002, 114, 2708–2711.
[15] a) R. Serwa, I. Wilkening, G. Del Signore, M. Mühlfeld, I. Claußnitzer, C. Weise, M. Gerrits, C. P. R. Hackenberger, Angew. Chem. Int. Ed. 2009, 48, 8234–8239; Angew. Chem. 2009, 121, 8382–8387; b) V. Böhrsch, T. Mathew, M. Zieringer, M. R. J. Vallée, L. M. Artner, J. Dernedde, R. Haag, C. P. R. Hackenberger, Org. Biomol. Chem. 2012, 10, 6211–6216; c) C. I. Schilling, N. Jung, M. Biskup, U. Schepers, S. Bräse, Chem. Soc. Rev. 2011, 40, 4840–4871.

[16] a) P. G. Schmidt, A. H.-J. Wang, I. C. Paul, J. Am. Chem. Soc. 1974, 96, 6189–6191; b) G. D. Schmidt, W. L. Duax, S. Fortier, J. Am. Chem. Soc. 1978, 100, 6725–6727; c) R. Lyazghi, A. Cuer, G. Dauphin, J. Juillard, J. Chem. Soc. Perkin Trans. 2 1992, 32–42.

[17] a) A. Huczynski, J. Rutkowski, I. Borowicz, J. Wietrzyk, E. Maj, B. Brzezinski, Bioorg. Med. Chem. Lett. 2013, 23, 5053–5056; b) P. B. Gupta, T. T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R. A. Weinberg, E. S. Lander, Cell 2009, 138, 645–659.

[18] a) M.-H. Abdulla, D. S. Ruelas, B. Wolff, J. Snedecor, K.-C. Lim, F. Xu, A. R. Renslo, J. Williams, J. H. McKerrow, C. R. Caffrey, PLoS Neglected Trop. Dis. 2009, 3, e478; b) J. Adovelande, J. Schrövel, Life Sci. 1996, 59, PL309–315.

[19] a) W. Hüttel, J. B. Spencer, P. F. Leadlay, Beilstein J. Org. Chem. 2014, 10, 361–368; b) J. Rutkowski, B. Brzezinski, BioMed. Res. Int. 2013, DOI: 10.1155/2013/162513.

[20] a) S. Dutta, J. R. Whicher, D. A. Hansen, W. A. Hale, J. A. Chemler, G. R. Condgon, A. R. H. Narayan, K. Håkansson, D. H. Sherman, J. L. Smith, G. Skiniotis, Nature 2014, 510, 512–517; b) J. R. Whicher, S. Dutta, D. A. Hansen, W. A. Hale, J. A. Chemler, A. M. Dosey, A. R. H. Narayan, K. Håkansson, D. H. Sherman, J. L. Smith, G. Skiniotis, Nature 2014, 510, 560–564.